These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27942203)

  • 1. Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.
    Perrone V; Saragoni S; Buda S; Broccoli A; Degli Esposti L
    Biologics; 2016; 10():157-165. PubMed ID: 27942203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.
    Stoppa G; D'Amore C; Conforti A; Traversa G; Venegoni M; Taglialatela M; Leone R;
    BioDrugs; 2018 Aug; 32(4):367-375. PubMed ID: 30030767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study.
    Hustrini NM; Siregar P; Setiawati A; Nugroho P
    Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
    Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
    Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
    Aapro M; Krendyukov A; Schiestl M; Gascón P
    BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.
    Kurtz JE; Soubeyran P; Michallet M; Luporsi E; Albrand H
    Onco Targets Ther; 2016; 9():6689-6693. PubMed ID: 27822071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.
    Giordano G; Mondello P; Tambaro R; Perrotta N; D'Amico F; D'Aveta A; Berardi G; Carabellese B; Patriarca A; Corbi GM; DI Marzio L; Licianci A; Berardi D; DI Lullo L; DI Marco R
    Mol Clin Oncol; 2015 Jul; 3(4):781-784. PubMed ID: 26171179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching Between Epoetins: A Practice in Support of Biosimilar Use.
    D'Amore C; Da Cas R; Rossi M; Traversa G
    BioDrugs; 2016 Feb; 30(1):27-32. PubMed ID: 26728875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
    Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
    BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.
    Broccoli A; Argnani L; Stefoni V; Gandolfi L; Zinzani PL
    Hematol Oncol; 2018 Feb; 36(1):136-143. PubMed ID: 28332724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital.
    Santoleri F; Romagnoli A; Costantini A
    Future Oncol; 2019 Jan; 15(1):45-51. PubMed ID: 30468397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.
    Xue W; Lloyd A; Falla E; Roeder C; Papsch R; Bühler K
    Int J Womens Health; 2019; 11():319-331. PubMed ID: 31191040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.